title: The prognosis of patients with alcoholic liver disease. An international randomized, placebo-controlled trial on the effect of malotilate on survival.
abstract: The aim of this study was to examine the effect of malotilate on survival in patients with alcoholic liver disease and to determine prognostic variables for survival. Four hundred and seven patients with alcoholic liver diseases, from seven European liver units, entered a randomized placebo-controlled, double-blind trial: 140 patients received malotilate 1500 mg/day, 133 patients received 750 mg/day, and 134 patients received placebo. The patients were included in the study over a period of 3 1/2 years, and the study was closed 1 year after the entry of the last patient. Eighty-four patients died (35, 19, 30 patients in groups 1500 mg/day, 750 mg/day, and placebo, respectively). Survival was slightly better in the 750 mg/day group than in the two other treatment groups, when tested by conventional log-rank tests (p = 0.06). However, a treatment effect was supported by a highly significant (p = 0.006) non-proportionality of the death intensity in patients receiving 750 mg/day against those receiving either 1500 mg/day or placebo. Prognostic variables for survival were evaluated using the multiple Cox regression analysis of clinical and laboratory variables and with or without liver histology variables, as determined at entry into the study. The analysis was stratified for the three treatment regimens. In the analysis including liver histology variables, independent significant prognostic variables were: years of high alcohol intake, prothrombin index, alkaline phosphatases, creatinine, immunoglobulin M, white blood cell count, and liver cell steatosis. In the analysis without liver histology variables, prognostic variables were: years of high alcohol intake, prothrombin index, alkaline phosphatases, creatinine, and immunoglobulin M.
authors.affiliation: Rigshospitalet, Copenhagen, Denmark.
authors.forename: S
authors.initials: S
authors.lastname: Keiding
authors.forename: J H
authors.initials: JH
authors.lastname: Badsberg
authors.forename: U
authors.initials: U
authors.lastname: Becker
authors.forename: K D
authors.initials: KD
authors.lastname: Bentsen
authors.forename: O
authors.initials: O
authors.lastname: Bonnevie
authors.forename: J
authors.initials: J
authors.lastname: Caballeria
authors.forename: J
authors.initials: J
authors.lastname: Eriksen
authors.forename: F
authors.initials: F
authors.lastname: Hardt
authors.forename: N
authors.initials: N
authors.lastname: Keiding
authors.forename: M
authors.initials: M
authors.lastname: Morgan
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005060:Europe; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007391:International Cooperation; D008099:Liver / Q000473:pathology; D008108:Liver Diseases, Alcoholic / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008314:Malonates / Q000627:therapeutic use*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D015996:Survival Rate
chemical_list: D008314:Malonates; C024808:diisopropyl 1,3-dithiol-2-ylidenemalonate